Skip to content

Reported November 13, 2025 · Before market open

Revenue estimate$10.4M
EPS estimate-$0.67

Next report

Aug 12, 2026 (in a month)
Revenue estimate$15.2M
EPS estimate-$2.95

Financials

Q3 2025

Income statement

See full
Revenue$7.4M
Gross profit$5.1M
Operating income-$15.4M-650%
Net income-$16.2M-858%

Balance sheet

See full
Cash & equivalents$14.2M+1,032%
Total debt$2.8M
Total equity$58.3M+4,179%
Total assets$126.4M+5,808%

Cash flow

See full
Operating cash flow-$15.3M-8,487%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$85.9M
Enterprise value$74.55M
P/S11.6×

Profitability

See full
Gross margin68.7%
Operating margin-300.4%
Net margin-318.4%

Returns & leverage

See full
Debt / equity
Current ratio+1.4×

Versus estimates

Ask the moment Pelthos Therapeutics Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Pelthos Therapeutics Inc. report Q3 2025 earnings?
Pelthos Therapeutics Inc. (PTHS) reported Q3 2025 earnings on November 13, 2025 before market open.
What were Pelthos Therapeutics Inc.'s Q3 2025 revenue and EPS?
Pelthos Therapeutics Inc. reported revenue of $7.4M and diluted EPS of $-5.30 for Q3 2025.
Did Pelthos Therapeutics Inc. beat estimates in Q3 2025?
Revenue missed the consensus estimate of $10.4M by $3.0M. EPS missed the consensus estimate of $-0.67 by $4.63.
Where can I find Pelthos Therapeutics Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001753926-25-001766) and the 10-Q periodic report (0001753926-25-001764) directly on SEC EDGAR. The filing index links above go to sec.gov.